The brief

Analyst view

• AVITI is the first venture-backed benchtop sequencer competitor to Illumina; VITARI adds high-throughput.
• Samsung led $175M Series E June 2026, becoming largest shareholder.
• Expanding from sequencing into RNA, proteins, and spatial biology on one platform.

Technical approach

As reported

Benchtop

Compact cost-efficient sequencer

AVITI fits individual labs; delivers high throughput at lower cost per genome than competitors.

High-throughput

VITARI for large labs

VITARI scales capacity for labs running many samples per week, balancing throughput with footprint.

Multiomics

RNA and proteins on one platform

Element expands into RNA, proteins, spatial and single-cell on same instrument.